Save the date for the 11th Annual HT-ADME Conference!

Webinar HT-ADME 2021

DOWNLOAD HT-ADME 2021 PROGRAM GUIDE HERE

June 22-23, 2021

 

Plenary Speaker for 2021

 

Marcel Hop, PhD, Vice President, DMPK, Genentech

Influencing Design with in silico ADME Models

      
           
   

Kathy Giacomini, PhD, Professor, Bioengineering, Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, School of Pharmacy, UCSF

High Throughput Screening and Real World Biomarkers to Predict Drug-Drug and Drug-Nutrient Interactions: Implications to poly pharmacy associated with COVID

      
           
 

Yurong Lai, Gilead, PhD, FAAPS, Sr. Director, Drug Metabolism, Gilead Sciences

Title TBA - ADME data on Remdesivir/treatment efficacy

      
           
 

David Rodrigues, PhD, Senior Scientific Director, Head of Transporter Sciences Group, Pfizer

Liquid Biopsy in ADME: Where are We Now and Where are We Going?

      

Speakers Confirmed for 2021

 

Dallas Bednarczyk, PhD, Senior Principal Scientist, Novartis Institutes for Biomedical Research

The Impact of Ion Trapping on the Cellular Accumulation of Highly Permeable Low Molecular Weight Acidic Drugs

  

Bo Feng, PhD, Director, DMPK, Vertex Pharmaceuticals

Validation of PXB Chimeric Mice with Humanized Liver to Predict Human Liver-to-Plasma Kpuu of OATP1B1 Substrates

           
 

Na Li, PhD, Senior Research Scientist II, C4 Therapeutics

Improved IVIVE for Hepatic Clearance Prediction: The Impact of Albumin on Hepatic Uptake

  

Iain Martin, Vice President, DMPK, Relay Therapeutics 

Unbound Volume of Distribution as a Foundational Parameter in Drug Design

           
 

Randy Miller, Senior Investigator, Merck

Unbound Volume of Distribution as a Foundational Parameter in Drug Design

  

Mark Milton, PhD, Ophthalmology Therapeutic Area Head, PK Sciences at Novartis Institutes for BioMedical Research (NIBR)

AAV Gene Therapies - New Opportunities for ADME Scientists

           
   

Xin Xu, PhD, Senior Scientist, National Center for Advancing Translational Sciences (NCATS), NIH

NCATS ADME Datasets and In Silico Models Derived from These Datasets

 

    

Albert Li, PhD, President & CEO at In Vitro ADMET Laboratories 

999Elite Cryopreserved Human Hepatocytes

 

           

 
 

Peter Tatrai, PhD, Senior Scientist, R&D, Solvo Biotechnology A Charles River  Company

Mechanistic Insights Into the Inhibitor Preincubation Effect

   

Beth Williamson, PhD, DMPK Project Representative, Early Oncology DMPK, AstraZeneca, UK

Quantitative and Qualitative Aspects of PROTAC Metabolism: Do they differ from small molecule?

   

Mark Wenlock, PhD, Physical Chemistry Team Leader @ Cyprotex 

High Throughput Physical Chemistry Assays: Advances and Application

   

Ismael Zamora, PhD, CFO @ Lead Molecular Design, S.L. 

HT-ADME: From Data to Knowledge. Generate Data to Feed AI Model Operation and Reach Optimal Compound Deisgn

   

Kenneth R. Brouwer, PhD, RPh, Vice President, Technologies-ADME-TOX @ BioIVT

Importance of Polarized Models for the Evaluation of Hepatic Transporter Based Drug Interactions 

     

 

Session Topics Proposed for 2021 include: 

New Modalities

New ADME Technologies

Transporters

PBPK Modeling

 

Join our Linkedin Group:

Workshops

Session I: ADME Prediction Tools for Old and New Therapeutic Modalities

Session II: Transporter-Mediated Drug Disposition

Session III: Bioanalysis of New Therapeutic Modalities

Sessin IV: New Clearance Prediction Models

 

Registration

Click here to register for the HT-ADME conference online.

HT-ADME 2021 will take place June 22-23, 2021

Virtual Event

 

The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3

Updates

Sign Up Today!

Privacy Policy